Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver
disease in industrialized countries worldwide, and has become a serious public health issue …

Background Decreased activity of the enzyme paraoxonase-1 (PON1) has been
demonstrated in cardiovascular diseases. Statins, the forefront of pharmacotherapy for …

Introduction/Aim Considering the high prevalence of non-alcoholic fatty liver disease
(NAFLD) in individuals with type 2 diabetes mellitus (DM2), we aimed to investigate the …

Nonalcoholic fatty liver disease (NAFLD) represents a broad spectrum of histological
abnormalities with clinical presentations ranging from hepatic steatosis to nonalcoholic …

Statins, the lipid-lowering drugs, and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic
steatohepatitis (NASH), a lipid-related pathology, share a complex relationship, one known …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the western
world with prevalence of 20–33%. NAFLD comprises a pathological spectrum. Nonalcoholic …

Abstract Background and Aims Non-alcoholic fatty liver disease (NAFLD) has become a
significant cause of chronic liver disease in developed countries, as a result of the worldwide …

Atherogenic dyslipidemia is characterized by increased triglyceride-rich lipoproteins and low
high-density lipoprotein cholesterol concentrations. It is highly prevalent in non-alcoholic …

Background: Nitro-oxidative stress (NOS) has been implicated in the pathophysiology of
psychiatric disorders. The activity of the polymorphic antioxidant enzyme paraoxonase 1 …

Oxidative stress is a determinant of liver steatosis and the progression to more severe forms
of disease. The present study investigated the effect of paraoxonase-1 (PON1) deficiency on …